Autolus Therapeutics plc ADR
Autolus Therapeutics plc ADR (AUTL) Straddle
AUTL straddle scan found 2 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 69.6%.
Read more
Trading a AUTL straddle lets you take a pure volatility position on Autolus Therapeutics plc ADR without committing to a direction. Autolus Therapeutics plc ADR's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate AUTL straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on AUTL profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Autolus Therapeutics plc ADR stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the AUTL straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.
It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the AUTL straddle is the cleanest expression of that view. Our scanner prices every AUTL straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a AUTL straddle into a catalyst or short a AUTL straddle to harvest decay, the options straddle setups that matter are all in one place.
| Mar 19, 2027 | 2.50 | $0.95 | 178 | 8% | 69.6% | $3.45 | $1.55 | 63 |
| Dec 18, 2026 | 2.50 | $0.80 | 87 | 8% | 63.9% | $3.30 | $1.70 | 3 |
As of September 22, 2026
Find the right straddle before volatility moves
Track AUTL straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→